AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

LATHAM, N.Y.--(BUSINESS WIRE)--Jul 23, 2025-

CDK4/6 inhibitor combination could overcome drug resistance in advanced prostate cancer

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone therapy based on the inhibition of androgen receptor signaling (ARPi) is the mainstay of treatment for metastatic prostate cancer (mPC). However, cancer drug resistance ultimately arises, highlighting the need for more effective therapeutic strategi…

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

CDK4/6 & Senolytic Therapies for Advanced Prostate Cancer

New Drug Sequencing Shows Promise in Overcoming Prostate Cancer Resistance A novel treatment strategy combining CDK4/6… The post CDK4/6 & Senolytic Therapies for Advanced Prostate Cancer appeared first on TIme News.